A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Immuneering Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 248,700 shares of IMRX stock, worth $661,542. This represents 0.0% of its overall portfolio holdings.

Number of Shares
248,700
Holding current value
$661,542
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.28 - $2.75 $318,336 - $683,925
248,700 New
248,700 $318,000
Q2 2022

Aug 15, 2022

SELL
$3.89 - $7.81 $8,558 - $17,182
-2,200 Reduced 16.54%
11,100 $60,000
Q1 2022

May 16, 2022

BUY
$6.47 - $16.99 $86,051 - $225,966
13,300 New
13,300 $86,000

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $70.2M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.